WO2014049817A1

WO2014049817A1 - Medical member

Info

Publication number: WO2014049817A1
Application number: PCT/JP2012/075031
Authority: WO
Inventors: 周平三枝; 克彦清水
Original assignee: テルモ株式会社
Priority date: 2012-09-28
Filing date: 2012-09-28
Publication date: 2014-04-03

Abstract

Provided is a medical member which enables mononuclear cells, which act as angiogenic factors, to be held in a blood vessel in a living body for a long period and can reduce an ischemic disease treatment burden on a patient. The medical member (10) is provided with: a filter part (20) which is to be introduced into a blood vessel in a living body and can capture mononuclear cells which act as angiogenic factors; and a holding part (30) which can hold the filter part at a desired position in the blood vessel.

Description

Medical material

The present invention relates to a medical member that promotes angiogenesis by capturing mononuclear cells that are angiogenic factors in blood vessels of a living body.

When arteriosclerosis or thrombus is formed and the state where the blood vessel is obstructed chronically continues, blood circulation failure occurs around the occluded site or at a site downstream of the occluded blood flow. In addition, when blood circulation failure occurs, an ischemic state is caused, and the ischemic state is sustained, and necrosis is caused in the living tissue. In recent years, as a treatment method for such vascular occlusion, there is a treatment method for improving blood circulation by introducing an angiogenic factor around an ischemic site to develop a collateral circulation path to an artery present in the ischemic site. Proposed.

As a technique related to the above therapeutic method, Patent Document 1 below discloses an angiogenic agent containing hydrogel particles carrying an angiogenic factor and a method for introducing the same. In this treatment method using an angiogenic agent, a hydrogel particle is introduced transarterially into a poorly developed collateral circulation using a medical device such as a catheter, and the hydrogel particle is introduced into a blood vessel in a predetermined manner. It is allowed to stay for a period to promote the development of collateral circulation. By developing collateral circulation, blood flow at the ischemic site is increased to try to treat ischemic diseases.

JP-A-2005-104910

When the above-mentioned angiogenic agent is placed in a blood vessel, hydrogel particles disappear irregularly and disperse, so that there is a possibility that the effect of developing collateral circulation cannot be obtained sufficiently. For this reason, it is necessary to continuously administer the angiogenic agent in a relatively short period of time. In connection with this, the number of times the catheter is introduced into the living body, and the living body is punctured to introduce the catheter. Since the frequency | count etc. will increase, the burden to the patient used as administration object will become large.

The present invention has been made in view of the above problems, and enables mononuclear cells that are angiogenic factors to remain in the blood vessels of a living body for a long period of time, and thus to patients associated with treatment of ischemic diseases. It aims at providing the medical member which can reduce a burden.

(1) For promoting angiogenesis, comprising: a filter part that is introduced into a blood vessel of a living body and captures a mononuclear cell that becomes an angiogenic factor; and a holding part that holds the filter part at a predetermined site in the blood vessel. Medical member.

(2) The blood vessel is a collateral circulation path located on the central side of the living body with respect to the ischemic site formed in the living body, and the collateral circulation path is captured by capturing the mononuclear cells by the filter unit. The medical member for promoting angiogenesis according to (1) above, wherein the growth of the collateral circulation is promoted so as to extend toward a blood vessel existing in the ischemic site.

(3) The holding unit holds the filter unit movably so that the filter unit moves from the upstream side to the downstream side of the blood flow as the blood vessel grows. A medical member for promoting angiogenesis as described in 2).

(4) The angiogenesis according to (3), wherein the holding part is formed so that the filter part can be held with respect to the blood vessel by bringing at least a part of the holding part into contact with an inner wall of the blood vessel. Medical member for promotion.

(5) The angiogenesis-promoting medical member according to (4), wherein the holding part has a spherical or polygonal frame structure in which the filter part is disposed inside.

(6) The medical member for promoting angiogenesis according to any one of (1) to (5) above, wherein the filter portion has an eye roughness of 12 to 20 μm.

(7) The blood vessel is an internal iliac artery located closer to the center of the living body than the ischemic site formed in the living body, and the internal iliac artery is captured by capturing the mononuclear cells by the filter unit. The medical member for promoting angiogenesis according to the above (1), which promotes the growth of the collateral circulation so as to extend toward the sub-knee artery at the ischemic site.

According to the invention described in (1) above, a mononuclear cell that becomes an angiogenic factor is captured in a blood vessel of a living body into which a medical member has been introduced, and the mononuclear cell is placed on a predetermined site in the blood vessel for a long time. It is possible to keep over. For this reason, the frequency | count of introducing a medical device into a patient's blood vessel within the treatment period of an ischemic disease can be reduced, and the burden on the patient accompanying the treatment of an ischemic disease can be reduced.

According to the invention described in (2) above, the blood circulation in the ischemic site can be efficiently improved by promoting the growth of the collateral circulation so as to extend to the blood vessel in which the ischemic site exists.

According to the invention described in (3) above, since the filter unit can be moved from the upstream side to the downstream side of the blood flow along with the growth of the blood vessel, the peripheral portion of the blood vessel according to the growth of the blood vessel Can capture mononuclear cells, and can promote blood vessel growth from the peripheral side more effectively.

According to the invention described in (4) above, it is possible to appropriately change the position where the holding portion and the blood vessel come into contact with the growth of the blood vessel, so that the blood flow from the upstream side to the downstream side can be changed. The filter part can be moved smoothly.

According to the invention described in (5) above, since the holding part has a spherical frame structure or a polygonal frame structure, the contact state between the holding part and the blood vessel can be stably maintained. In addition, the filter unit can be moved smoothly as the blood vessel grows.

According to the invention described in (6) above, monocytes can be suitably captured in the filter section.

According to the invention described in (7) above, the internal iliac artery can be connected to the inferior arterial artery at the ischemic site, and blood circulation at the ischemic site can be improved efficiently.

It is a general-view figure which shows the medical member which concerns on embodiment of this invention. It is a figure which shows typically the lower limb of the biological body in which the ischemic site | part was formed. It is a figure for demonstrating the effect | action of the medical member which concerns on embodiment, Comprising: It is a figure which simplifies and shows a mode that a medical member is introduce | transduced in the artery which is a treatment object. It is a figure for demonstrating the effect | action of the medical member which concerns on embodiment, Comprising: It is a figure which simplifies and shows a mode that a mononuclear cell is introduce | transduced in the artery which introduce | transduced the medical member. It is a figure for demonstrating the effect | action of the medical member which concerns on embodiment, Comprising: It is the elements on larger scale which show typically the state by which the mononuclear sphere was capture | acquired by the filter part of the medical member. It is a figure for demonstrating the effect | action of the medical member which concerns on embodiment, Comprising: The partial enlarged view which shows typically a mode that the growth of a collateral circulation is accelerated | stimulated by the mononuclear sphere captured by the filter part of the medical member It is. It is a figure which shows typically the lower limb of the biological body by which the growth of the collateral circulation was promoted by the medical member which concerns on embodiment. It is the elements on larger scale for demonstrating the modification 1 of a medical member. It is the elements on larger scale for demonstrating the modification 2 of a medical member. It is the elements on larger scale for demonstrating the modification 3 of a medical member.

Hereinafter, the present invention will be described based on embodiments with reference to the drawings. FIG. 1 is a diagram for explaining the overall configuration of the medical member according to the embodiment, and FIGS. 2 to 6 are diagrams for explaining the operation of the medical member according to the embodiment. In the description of the drawings, the same elements are denoted by the same reference numerals, and redundant description is omitted. In addition, the dimensional ratios in the drawings are exaggerated for convenience of explanation, and may be different from the actual ratios.

Referring to FIG. 1, FIG. 5A, and FIG. 5B, the medical member 10 according to the embodiment of the present invention is generally a filter that is introduced into a blood vessel of a living body and captures a mononuclear cell 40 that becomes an angiogenic factor. An angiogenesis-promoting medical member 10 comprising a portion 20 and a holding portion 30 that holds the filter portion 20 at a predetermined site in the blood vessel.

Referring to FIG. 2, an ischemic disease to be treated by the medical member 10 will be briefly described. FIG. 2 schematically shows a leg 50 of a patient suffering from an ischemic disease. In the figure, the central side (upper side in the figure) of the living body with respect to the broken line part A indicates a site P1 in which normal blood flow is secured, and the peripheral side of the living body with respect to the broken line part A (lower side in the figure). Indicates ischemic site P2.

The ischemic disease is caused by the formation of a stenotic site N that causes blood flow such as arteriosclerosis and thrombus in blood vessels, resulting in decreased blood circulation and formation of a site in the living body where blood supply is not sufficiently distributed. This is a disease in which such a site becomes chronically ischemic. In addition, persistence of the ischemic state causes necrosis of living tissue. In the illustrated example, a stenotic site N or the like is formed for some reason in an artery such as the external iliac artery 60 or the like that inherently has a function of distributing blood to the peripheral part of the lower limb 50 of a living body, and sufficient blood to the peripheral side is formed. As a result, it becomes impossible to secure the flow, and a state in which the ischemic site P2 is formed due to this is shown.

The medical member 10 is used to improve and treat an ischemic disease by capturing the mononuclear cells 40 as angiogenic factors in the blood vessel by being introduced into the blood vessel of a patient suffering from an ischemic disease. It is done. More specifically, the collateral circulation 70 is selectively placed in an ungrown collateral circulation 70 (a small-sized artery at the periphery of the artery, for example, the internal iliac artery) and captured by mononuclear cells. Is connected to an artery such as the inferior arterial artery 78 of the ischemic site P2, and the blood flowing through the external iliac artery 60 is diverted by bypassing the stenotic site N to increase the blood flow volume in the ischemic site P2. Make it possible. In the specification, “promoting the growth of blood vessels (collateral circulation)” means extending the peripheral side of the blood vessels, increasing the diameter of the blood vessels, or renewing the blood vessels.

As the mononuclear cells according to the embodiment, those existing in body fluids and blood (bone marrow fluid, peripheral blood, umbilical cord blood, etc.) that are basic fibroblast growth factor (bFGF) precursors can be used. For example, mononuclear cells (lymphocytes, NK spheres, NKT cells, monocytes, etc.) obtained by removing red blood cells, platelets, granulocytes and the like from blood and further separating and concentrating them can be used. Separation and concentration can be performed by, for example, a known blood component separation device using a filter or centrifugal separation. As will be described later, it is possible to provide a treatment method that promotes the development of angiogenesis by using the mononuclear cells generated by the above method together with the medical member 10. Also, there is provided a treatment method for promoting the development of angiogenesis by capturing the mononuclear cells in the blood flowing in the blood vessel into which the medical member 10 has been introduced without supplying the mononuclear cells from outside the living body. It can also be provided.

Next, each configuration of the medical member 10 will be described.

Referring to FIG. 1, the filter unit 20 included in the medical member 10 is a part provided for capturing the mononuclear cells 40 in the blood vessel. As shown in the figure, the filter unit 20 can be configured by, for example, a mesh-like filter structure. The coarseness of the filter portion 20 is not particularly limited as long as the mononuclear sphere 40 can be captured, but can be formed to 12 to 20 μm, for example. The reason for forming such a mesh size is as follows. Monocytes contained in the mononuclear cells 40 effectively act as components that promote angiogenesis. In general, the average diameter of the monocytes is 12 to 20 μm. Therefore, by forming a mesh with the dimensions as described above, monocytes can be efficiently captured in the blood vessel, and the promotion of angiogenesis can be improved.

Although there is no restriction | limiting in particular as a material which comprises the filter part 20, For example, as a metal material, stainless steel, a tantalum or a tantalum alloy, platinum or a platinum alloy, gold or a gold alloy, a cobalt base alloy, a cobalt chromium alloy, a titanium alloy And niobium alloys. Resin materials include polytetrafluoroethylene, polyethylene, polypropylene, polyethylene terephthalate, cellulose acetate, cellulose nitrate, polylactic acid, polyglycolic acid, copolymers of lactic acid and glycolic acid, polycaprolactone, polyhydroxybutyrate Examples thereof include biodegradable polymer materials such as valerate.

The holding part 30 provided in the medical member 10 is a part provided to hold the filter part 20 at a predetermined part in the blood vessel. As shown in FIG. 5A, the holding unit 30 prevents the unnecessary movement of the filter unit 20 after the medical member 10 is introduced into the blood vessel and is captured by the filter unit 20 and the filter unit 20. 40 can be held in place in the blood vessel.

The holding unit 30 has a spherical frame structure in which the filter unit 20 is disposed on the inside. As shown in FIG. 1, the filter part 20 and the holding | maintenance part 30 are comprised integrally so that the medical member 10 may have a spherical external shape as a whole. In addition, the holding unit 30 is provided so that the filter unit 20 can be moved along with the renewal or growth of a blood vessel into which the medical member 10 has been introduced. Specifically, as described later, when the medical member 10 is introduced into the collateral blood passage 70 and the collateral blood passage 70 grows, the holding unit 30 moves the blood flow along with the growth of the collateral blood passage 70. The filter unit 20 is moved from the upstream side to the downstream side (see FIGS. 5A and 5B). In addition, since the medical member 10 which concerns on embodiment is comprised by the filter part 20 and the holding | maintenance part 30, the movement of the filter part 20 means the movement of the medical member 10 whole in other words.

The holding unit 30 can be configured to hold the filter unit 20 with respect to the blood vessel, for example, by bringing at least a part of the holding unit 30 into contact with the blood vessel inner wall 71. The reason for this configuration will be described. As shown in FIGS. 5A and 5B, when the growth of the collateral circulation path 70 into which the medical member 10 has been introduced is promoted, the collateral circulation path 70 starts to extend from the peripheral side 73. In a state before the growth of the collateral blood circulation path 70 is promoted, the holding unit 30 maintains a state in contact with the inner wall 71 of the collateral blood circulation path 70 and is captured by the filter unit 20 and the filter unit 20. The mononuclear sphere 40 is held at a predetermined site. Then, when the growth of the collateral circulation 70 is promoted by the mononuclear cells 40 captured by the filter unit 20 and the peripheral side 73 of the collateral circulation 70 is expanded, the holding unit 30 moves along the inner wall of the blood vessel along with the expansion. The filter unit 20 is moved to the distal side 73 of the collateral circulation path 70 by shifting the position where it comes into contact with 71. Therefore, it is possible to move the mononuclear cells 40 captured by the filter unit 20 together with the filter unit 20 to the peripheral side 73 of the collateral circulation path 70 and to keep the mononuclear cells 40 at the moved position. For this reason, it becomes possible to promote the growth of the collateral circulation path 70 from the peripheral side 73 more effectively.

The position where the holding unit 30 is brought into contact with the collateral blood circulation path 70 is not particularly limited as long as the filter unit 20 can move as the collateral blood circulation path 70 grows. For example, as shown in FIG. 5 (A), the collateral blood circulation path 70 may be brought into contact with the side wall portion and the collateral blood circulation path 70 at the distal end portion 75, or may be brought into contact with any one of the positions. May be.

Although there is no restriction | limiting in particular as a material which comprises the holding | maintenance part 30, For example, the material similar to the material which comprises said filter part 20 can be used. Further, in the present embodiment, the holding unit 30 is configured as a frame structure so as to form the outer shape of the medical member 10, and the filter unit 20 and the holding unit 30 are configured by separate members. The filter unit 20 and the holding unit 30 may be integrally configured in advance. As a method of configuring in this way, for example, a method of manufacturing the filter unit 20 so that the filter unit 20 itself holds a predetermined outer shape and omitting the installation of the holding unit 30 having a frame structure may be mentioned. Further, if manufactured in this way, the outer portion of the filter unit 20 can function as the holding unit 30 as it is. Therefore, the medical member 10 can be configured only by the filter unit 20 having the function of the holding unit 30.

Next, the operation of the medical member 10 will be described.

In the following description, an example in which the medical member 10 is applied to a patient with an ischemic disease in which the ischemic site P2 is formed on the lower limb 50 as shown in FIG. 2 will be described.

First, prior to the introduction of the medical member 10 into the blood vessel, the ischemic site P2 that is the site to be treated is specified. As a specifying method, a contrast examination or the like known in the medical field can be employed. Prior to performing a contrast examination, an access port for introducing a contrast agent into a blood vessel is appropriately provided in the living body.

After specifying the site to be treated, as shown in FIG. 3, the medical member 10 is introduced into the collateral circulation 70 located on the center side of the living body with respect to the ischemic site P2 using the catheter 80. Since the medical member 10 is formed in a spherical shape, the medical member 10 can be smoothly moved to the distal side 73 of the collateral blood circulation 70 by being placed on the blood flow of the collateral blood circulation 70.

The catheter 80 is guided to the vicinity of the entrance of the collateral blood circulation 70 through the external iliac artery 60 connected to the collateral blood circulation 70 into which the medical member 10 is introduced, for example. As the catheter 80, a catheter known in the medical field can be used. For example, the catheter 80 can be introduced using a guide wire via the access port described above. In addition, the medical member 10 can be introduced into the lumen of the catheter 80 using a syringe pump or the like known in the medical field.

Next, as shown in FIG. 4, the mononuclear cells 40 are introduced into the collateral circulation 70 using the catheter 80. In FIG. 4, the mononuclear sphere 40 is indicated by a black circle for easy understanding.

The supplied mononuclear sphere 40 can be collected in advance by the above-described centrifugation method or the like. In consideration of biocompatibility with the patient, it is preferable to use the mononuclear cell 40 collected from blood or bone marrow flowing through the peripheral blood vessels of the patient.

In addition, when it is possible to promote the growth of the collateral circulation path 70 by capturing monocytes contained in blood flowing in the collateral circulation path 70 in the filter unit 20, the mononuclear as described above. The operation of supplying the sphere 40 from outside the living body may be omitted.

As shown in FIG. 5A, the filter unit 20 captures the mononuclear cells 40 in the collateral circulation path 70 and holds the mononuclear cells 40 at a predetermined position. Then, when the growth of the collateral circulation 70 is promoted by the mononuclear cells 40, the collateral circulation 70 develops so as to extend from the peripheral side 73 as shown in FIG. At this time, the filter unit 20 moves from the upstream side to the downstream side of the blood flow with the growth of the collateral circulation path 70 (indicated by an arrow in the figure), and the mononuclear cell 40 is located at a more distal side 73 site. Makes it possible to capture.

Then, as shown in FIG. 6, each collateral circulation path 70 into which the medical member 10 has been introduced grows so as to extend toward the inferior knee artery 78 in the ischemic region P2. As a result, the collateral circulation 70 and the inferior knee artery 78 are connected, so that the external iliac artery 60 bypasses the stenotic site N and joins to the inferior artery 78. It becomes possible to supply blood from the external iliac artery 60 to the inferior artery 78, and blood circulation at the ischemic site P2 can be improved.

When the development of the collateral blood circulation 70 is not sufficient, when the development of the collateral blood circulation 70 is promoted over a long period of time, or when further development of the collateral blood circulation 70 is promoted, The series of operations described above can be repeated in accordance with the period during which the nuclear sphere 40 disappears.

As described above, the method for treating ischemic disease using the medical member according to the present embodiment includes (i) a filter unit that captures mononuclear cells that are angiogenic factors, and the filter unit is a predetermined part of the blood vessel. A step of introducing a medical member for promoting angiogenesis comprising a holding part held in a site into a blood vessel of a living body.

Also, in the step (i), the medical member is introduced into a collateral circulation located on the central side of the living body with respect to the ischemic site formed in the living body. Then, by capturing the mononuclear cells by the filter unit, the growth of the collateral circulation is promoted so that the collateral circulation extends toward a blood vessel existing in the ischemic site. To do.

Further, after the step (i), there is a step (ii) of supplying mononuclear cells to the collateral circulation.

Further, the filter unit is moved from the upstream side to the downstream side of the blood flow along with the growth of the collateral circulation.

The steps (i) and (ii) are performed a plurality of times during a predetermined period.

Further, the collateral circulation is the internal iliac artery, and the internal iliac artery is grown toward the inferior arterial artery at the ischemic site.

As described above, according to the medical member 10 according to the present embodiment, the mononuclear cell 40 that is an angiogenic factor is captured in the blood vessel of the living body into which the medical member 10 is introduced, and the mononuclear cell 40 is captured. It is possible to remain at a predetermined site in the blood vessel for a long time. For this reason, the frequency | count of introducing a medical device into a patient's blood vessel within the treatment period of an ischemic disease can be reduced, and the burden on the patient accompanying the treatment of an ischemic disease can be reduced.

In addition, when the medical member 10 is introduced into the collateral circulation path 70 located on the central side of the living body with respect to the ischemic site P2 formed in the living body, the medical member 10 is extended to the blood vessel 78 where the ischemic site P2 exists. Since it becomes possible to promote the growth of the auxiliary blood circulation path 70, the blood circulation in the ischemic site P2 can be improved efficiently.

Further, when the medical member 10 is configured to move the filter unit 20 from the upstream side to the downstream side of the blood flow as the collateral blood passage 70 grows, The mononuclear cells 40 can be captured at the site of the peripheral side 73 of the collateral circulation 70 in accordance with the growth of the 70, and the growth of the collateral circulation 70 from the peripheral side 73 is further effectively promoted. Can do.

Further, when the holding part 30 of the medical member 10 is formed so as to hold the filter part 20 with respect to the collateral blood circulation path 70 by bringing at least a part of the holding part 30 into contact with the blood vessel inner wall 71. Since the position where the holding unit 30 and the collateral blood circulation 70 abut can be appropriately changed as the collateral blood circulation 70 grows, the filter from the upstream side to the downstream side of the blood flow can be changed. The part 20 can be moved smoothly.

Moreover, when the holding | maintenance part 30 has the spherical frame structure by which the filter part 20 is arrange | positioned inside, the maintenance of the contact state of the holding | maintenance part 30 and the collateral circulation path 70 can be performed stably. . Furthermore, the filter unit 20 can be smoothly moved as the collateral circulation path 70 grows.

In addition, when the filter unit 20 is formed so as to have a coarseness of 12 to 20 μm, monocytes can be suitably captured in the filter unit 20.

Further, when the medical member 10 is introduced into the internal iliac artery located closer to the center of the living body than the ischemic site P2 formed in the living body, the internal iliac artery is connected to the inferior knee artery 78 at the ischemic site. Therefore, the blood circulation at the ischemic site can be improved efficiently.

Next, a modification of the above-described embodiment will be described. In addition, the description is abbreviate | omitted about the member same as the member demonstrated in embodiment mentioned above. Since the same material as that of the above-described embodiment can be used for the material constituting the filter part and the holding part, the description thereof is omitted.

FIG. 7A shows a medical member 110 according to the first modification. In the embodiment described above, the holding unit 30 is formed in a spherical frame structure. However, in this modification, the holding unit 30 is formed in a polygonal frame structure. When the holding part 30 is formed in a polygonal frame structure, each apex abuts against the inner wall 71 of the collateral circulation path 70, so that the filter part 20 formed inside the holding part 30 is in a predetermined position. Held in. Further, when the collateral circulation path 70 grows, the contact position between each apex and the inner wall 71 of the collateral circulation path 70 is appropriately changed as the collateral circulation path 70 grows. It is possible to move from the side to the downstream side. As described above, even when the holding unit 30 is formed in a polygonal frame structure, the contact state between the holding unit 30 and the collateral circulation path 70 can be stably maintained as in the case of the spherical frame structure. In addition, the filter unit 20 can be moved smoothly as the collateral circulation path 70 grows.

FIG. 7B shows a medical member 120 according to the second modification. In this modification, the outer shape of the medical member 120 is formed in a cylindrical shape configured such that the diameter increases from the proximal end side to the distal end side. The filter unit 20 is disposed on the upper surface of the medical member 120 and is also disposed inside the medical member 120. Since it becomes possible to capture the mononuclear sphere 40 in each of the

filter parts

121 and 122, it is possible to more effectively capture the mononuclear sphere 40 by the medical member 120. Moreover, the filter part 121,122 can also be provided with the function to hold | maintain by making a cylindrical lower end part etc. contact the inner wall of the collateral circulation path 70 partially. It is also possible to form the meshes of the

filter parts

121 and 122 in different sizes.

As shown in the present modification, the medical member according to the present invention only needs to have at least a function of capturing a mononuclear cell by the medical member and retaining the mononuclear cell at a predetermined site. The outer shape and the number of installed filter parts are not particularly limited.

FIG. 7C shows a medical member 130 according to Modification 3. In this modification, an arm portion that is engaged with the inner wall of the collateral circulation path 70 is employed as the holding portion 132 that holds the filter portion 20 so as to be movable. In the above-described embodiment and each modification, the structure in which the outer portion of the holding unit 30 is brought into contact with the inner wall 71 of the collateral circulation path 70 to hold the filter unit 20 is shown, but the holding unit has only such a configuration. It is not limited to these, The thing of a structure as shown in this modification can be employ | adopted.

Before the collateral blood circulation 70 grows, the arm portion as the holding portion 132 is locked to the inner wall 71 of the collateral blood circulation 70 with a relatively weak force. Then, when the collateral circulation path 70 grows and the diameter of the collateral circulation path 70 partially increases, the locking of the arm portion 132 to the inner wall 71 of the collateral circulation path 70 is released, and the filter section 20 is circulated. It can be moved downstream in the stream. As a material constituting the arm part 132, for example, the same material as that constituting the filter part 20 and the holding part 30 can be used. In the illustrated example, the installation of the frame structure holding unit is omitted, but a configuration in which a frame structure holding unit is further added may be used.

As shown in the present modification, the configuration for holding the filter portion movably only needs to be able to move the filter portion as the blood vessel grows, and the configuration can be appropriately changed within such a range. Is possible.

As mentioned above, although the medical member based on this invention was demonstrated based on embodiment and a some modification, this invention is not limited only to these embodiment and a modification, and description of a claim It is possible to change appropriately based on this.

For example, the application example in which the medical member 10 is introduced into the collateral blood circulation 70 of the lower limb 50 has been shown, but the site into which the medical member 10 is introduced is not limited to such a site. The medical member can be widely applied to sites other than the lower limbs for the purpose of retaining mononuclear cells in the blood vessels of the living body. In addition, the blood vessels to be applied are not limited to only the collateral circulation, and can be widely applied to various arteries and the like.

10, 110, 120, 130 medical member,
20 Filter section,
30 holding part,
40 mononuclear cells,
50 lower limbs,
60 external iliac artery,
70 collateral circulation,
71 inner wall of collateral circulation,
73 peripheral side of collateral circulation,
78 Knee arteries,
P1 normal site,
P2 ischemic site.

Claims

A filter part that is introduced into a blood vessel of a living body and captures a mononuclear cell that becomes an angiogenic factor;
A medical member for promoting angiogenesis, comprising: a holding unit that holds the filter unit at a predetermined site in the blood vessel.
The blood vessel is a collateral circulation located on the central side of a living body with respect to an ischemic site formed in the living body, and the collateral circulation is captured by the filter unit by capturing the mononuclear cells. The medical member for promoting angiogenesis according to claim 1, wherein the growth of the collateral circulation is promoted so as to extend toward a blood vessel existing in the region.
The said holding | maintenance part hold | maintains the said filter part so that a movement is possible so that the said filter part may move toward the downstream from the upstream of blood flow with the growth of the said blood vessel. Medical member for promoting angiogenesis.
The medical device for promoting angiogenesis according to claim 3, wherein the holding portion is formed so as to hold the filter portion with respect to the blood vessel by bringing at least a part of the holding portion into contact with the inner wall of the blood vessel. Element.
The medical member for promoting angiogenesis according to claim 4, wherein the holding portion has a spherical or polygonal frame structure in which the filter portion is disposed inside.
The medical member for promoting angiogenesis according to any one of claims 1 to 5, wherein the filter portion has an eye roughness of 12 to 20 µm.
The blood vessel is an internal iliac artery located on the center side of the living body with respect to an ischemic site formed in the living body, and the internal iliac artery is captured by the filter unit by capturing the mononuclear cells. The medical member for promoting angiogenesis according to claim 1, wherein the growth of the collateral circulation is promoted so as to extend toward the sub-knee artery of the site.